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A renewed understanding of Trauma Induced Coagulopathy (TIC) has implicated platelets as a crucial mediator and
potential therapeutic target in hemostasis. While the importance of abnormal coagulation tests is well described in
trauma, there is a paucity of data regarding the role of platelets in coagulopathy. New coagulation models, namely
the cell-based-model of hemostasis, have refocused attention toward the platelet and endothelium as key regulators of
clot formation. Although platelet dysfunction has been associated with worse outcomes in trauma, the mechanisms
which platelet dysfunction contributes to coagulopathy are poorly understood. The goal of this review article is to
outline recent advances in understanding hemostasis and the ensuing cellular dysfunction that contributes to the
exsanguination of a critically injured patient.
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Hemorrhage continues to be a leading cause of early,
potentially salvageable traumatic death. Mortality from
hemorrhagic shock occurs quickly, with 80% of patients
dying within the first 2 hours of hospital presentation
[1]. The ability to form hemostatic clot is critical to the
arrest of hemorrhage, yet in critically injured patients,
hemostasis is severely compromised with over 25% of
trauma patients presenting to the emergency room with
a complex, biochemical coagulopathy known as trauma
induced coagulopathy (TIC) [2-5]. Compared with pa-
tients who do not have coagulopathy, those with clotting
dysfunction have a threefold to fourfold greater mortality
[2,6,7].
The body’s ability to synthesize functional clot is crit-
ical to the arrest of hemorrhage, yet in critically injured
patients, hemostasis is severely compromised.
The platelet, or thrombocyte, is the cellular agent re-
sponsible for clot formation. Despite functioning as the
building block for hemostasis, the role of platelets in
trauma-associated coagulopathy has been largely under-
appreciated. It is clear that platelet count and functional
quality correlate with risk of death. Blood samples from
trauma resuscitations show that even subtle disturbances* Correspondence: Carrie.Sims@uphs.upenn.edu
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unless otherwise stated.in platelet quality and quantity can translate into a 10-fold
increase in mortality [7-10].
Historically, TIC was first noted in military casualties
when abnormalities were detected in routine lab studies
[11]. Elevations in the international normalized ratio
(INR), prothrombin time (PT) and the partial thrombo-
plastic time (PTT) led the trauma community to focus
their investigations on the protease- based reactions of
the clotting cascade [11,12]. TIC was purported to occur
in the setting of factor consumption and dilution from
massive volume resuscitation. In an effort to minimize
the hemodilution of clotting factors, resuscitation strat-
egies changed from crystalloid volume replacement to
transfusion with a more equalized ratio of packed red
blood cells to plasma and platelets. The transfusion of
platelets and factor rich plasma was correlated with im-
proved survival [13-15].
As research honed in on transfusion protocols, two im-
portant developments suggested that TIC involved more
complex mechanisms than simply hemodilution [16,17].
First, Brohi detected that coagulopathy was present in pa-
tients prior to fluid and blood product resuscitation.
In a retrospective review of 1088 trauma patients, 25%
of patients had a clinically detectable coagulopathy on
initial presentation and prior to fluid resuscitation [2].
Secondly, a new cell based coagulation model proposed
by Hoffman in 2001 emphasized platelets as active regu-
lators of thrombin activation [18-20].ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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The cell based model of hemostasis
Hemostasis in its simplest construct involves the pro-
duction of a platelet plug and generation of thrombin
and fibrin to produce a blood clot, or thrombus. In con-
trast to previous depictions of hemostasis, the cell-based
model depicts thrombus formation as a series of three
overlapping steps (initiation, amplification and propaga-
tion) rather than as a unidirectional proteolytic cascade
(Figure 1).
Initiation
The first stage of the cell-based coagulation is termed
“initiation”. The initiating signal for coagulation and pla-
telet activation is tissue factor (TF). Tissue factor is an
integral transmembrane glycoprotein that is variably
expressed on the surface of certain cells including fibro-
blasts. The receptor shares homology with the interferon
family of receptors, with a large extracellular portion
that binds coagulation factor VIIa. Injury to a blood vessel
wall exposes tissue factor to the plasma-based factor VIIa.
The TF-VIIa complex utilizes proteolysis–dependent sig-
naling to activate the coagulation factors Xa, and subse-
quently factor Va, leading to conversion of prothrombin
to thombin. Fibrinogen, calcium, and activated coagula-
tion factors (VIIa, Xa, Va , XIa, IXa) enhance thrombin









Figure 1 Initiation: Tissue Factor (TF) exposure binds factor VIIa. The
conversion of prothrombin to thombin. Thrombin generation activates p
Activation: At the site of injury, platelets bind to exposed collagen and un
Thrombin cleaves the VWF from the VWF/VIII complex thus activating fac
complexing with factor IX. Factor IXa is then able to diffuse towards the p
The prothrombinase complex is formed by the platelet membrane bound
activated platelet membrane can then catalyze the Xa/Va prothrombinase
Thrombin performs the final step in the deposition of fibrin clot by cleavinenvironment shelters thrombin from degradation by the
inhibitors antithombin III and TFPI (Tissue Factor Path-
way Inhibitor). Moreover, the thrombin that is retained at
the cell surface plays an important function in platelet ac-
tivation [20,21].
Amplification and activation
The scaffold of the prothrombinase complex centers
around the platelet. At the site of injury, platelets bind
to exposed collagen via a unique platelet glycoprotein,
GIb/IX/V. The G1b component of this receptor binds
Von Willebrand’s Factor (VWF) to tether the thrombo-
cyte to the extracellular scaffold, while glycoprotein VI
and α2β1 glycoprotein Ia-IIa reinforces this hold. By
complexing thrombocytes to the collagen matrix, an ad-
hesive platelet plug is formed at the site of injury that is
capable of withstanding the shear stress of blood flow.
Although platelets are partially activated by binding to
the extracellular matrix, full activation requires throm-
bin. Thrombin localizes to the platelet cell surface and
fully activates platelets via its serine protease-activated
receptors, PAR 1 and PAR 4. Protease–activated recep-
tors (PARs) are G-protein coupled receptors that are ac-
tivated by cleavage of their N terminus. In turn, PAR
receptors activate platelets by augmenting inositol phos-
phate metabolism and intracellular calcium. Downstream
G-protein signaling from PAR 1 and ADP activates RhoGranuole
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TF-VIIa complex activates factor Xa and factor Va leading to
latelets and initiates a positive feedback loop. Amplification and
dergo a cytoskeletal transformation to the activated phenotype.
tor VIII. Propagation: The tenase complex is formed by factor VIII
latelet surface where it binds the surface bound, activated factor VIIIa.
factor Va complexing with Xa formed from the tenase complex. The
complex to convert large amounts of prothombin to thrombin.
g fibrinogen to fibrin [20].
Saillant and Sims Molecular and Cellular Therapies  (2014) 2:37 Page 3 of 7dependent phosphorylation of the myosin light chain and
induces a cytoskeletal rearrangement in the activated
platelet [21,22]. This leads to the formation of pseudopo-
dia to increase surface contact with collagen and adjoining
platelets.
Additional platelets are attracted to the site of injury
and adhere to the platelet scaffold by their surface recep-
tor, glycoprotein IIb/IIIa (αIIbβ3). The plug apparatus
builds as activated thrombocytes release highly concen-
trated stores of factor V and other cofactors to form the
growing clot. Thrombin cleaves the VWF from the VWF/
VIII complex thus activating factor VIII at the platelet sur-
face. The sequestration of both activated factor V and fac-
tor VIII at the platelet surface provides the necessary
foundation for building the procoagulant complex to pro-
duce thrombin en-masse [20].
Propagation
Two complexes, the tenase complex and the prothrom-
binase complex, are formed at the platelet surface by ac-
tivated factor VIII and factor V, respectively. The tenase
complex is formed by factor VIII complexing with factor
IX. Factor IX is activated by tissue factor bearing cells.
Factor IXa is then able to diffuse towards the platelet
surface where it binds the surface bound, activated factor
VIIIa. The presence of the negatively charged platelet
phospholipid surface environment enhances the activity
of IXa/VIIa tenase complex. The tenase complex’s ability
to form factor Xa is increased 1500 fold [23]. The tenase
complex can therefore provide large amounts of factor
Xa, to activate the second complex, known as the pro-
thrombinase complex. The prothrombinase complex is
formed by the platelet membrane bound factor Va com-
plexing with Xa formed from the tenase complex. The
activated platelet membrane can then catalyze the Xa/Va
prothrombinase complex to convert large amounts of
prothombin to thrombin. Thrombin performs the final
step in the deposition of fibrin clot by cleaving fibrino-
gen to fibrin [20].
The prothrombinase reaction promotes a positive feed-
back loop. Increased thrombin stimulates further platelet
activation and increased granule release. Fibrinogen and
fibrin bind the integrin αIIbβ3 and promote platelet ag-
gregation and clot stabilization [24]. This subsequently re-
cruits more platelets and thus propagates new sites of
platelet- prothrombinase activity.
The platelet-fibrin plug is stabilized by factor XIIIa
which crosslinks fibrin and reinforces the clot with anti-
fibrinolytic proteins. In particular, thrombin–activatable
fibrinolysis inhibitor (TAFIa) is incorporated into ma-
trix. TAFIa prevents clot degradation by decreasing the
number of binding sites for endogenous plasminogen
and tissue plasminogen activator. Finally, the intracel-
lular portion of platelet integrin αIIbβ3 connects to theplatelet’s intracellular actin and myosin network. Bind-
ing of fibrin to the extracellular portion of this receptor
induces platelet contraction. The contractile force of
the platelet, in turn, adds stress to the fibrin network,
and subsequently causes clot retraction and stabilization
[21,25].
In addition to supplying a phospholipid membrane
structure for the coagulation complex to assemble, plate-
lets actively secrete granules containing co-reagents ne-
cessary for clot propagation. The process of degranulation
requires platelets to be activated. Secreted factors include
calcium, ADP, ATP, serotonin, pyrophosphate, β thrombo-
globulin, and activated factor Va. These small molecules
and proteins are critical cofactors for fibrin formation and
platelet activation.
The cell-based model of hemostasis has implicated ac-
tivated platelets as a crucial mediator of thrombus for-
mation. Platelet activation, however, is a highly energetic
process and and an emerging body of evidence has tied
platelet activation to mitochondria and mitochondrial
regulators of apoptosis [26,27]. Despite being anucleated
cells, platelets retain caspases and other key mediators
of apoptosis such as Bax, Bcl −2, and Calpain [26,28].
Moreover, the shrinkage, plasma membrane vesiculation,
and bleb formation of apoptotic cells is reminiscent of the
conformational changes observed in “activated” platelets.
Furthermore, activated platelets increase their expres-
sion of P-selectin (CD62) and exteriorize phosphatidyl-
serine (PS) on the platelet membrane: two events that
are recognized as caspase-dependent markers of cell
death in other cell lines [29]. While the significance of
these mitochondrial-mediated events in activated plate-
lets remains to be determined, the appearance of apop-
totic features in stored banked platelets has significant
clinical implications and correlates with decreased func-
tion in transfused platelets.
On the other hand, altered mitochondrial function
in circulating platelets might enhance platelet function
in vivo. An intriguing correlation has been established
between the mitochondrial membrane potential (ΔΨm)
and the creation of a specialized subgroup of platelets,
termed coated- platelets. Coated platelets are a select sub-
population of thrombocytes with escalated hemostatic
potency that are induced in vivo by dual agonism with
thrombin and collagen. Coated platelets use serotonin
to retain procoagulant factors (e.g. factor V, fibrinogen,
fibrin, VWF, fibronectin, α2-antiplasmin and thrombos-
pondin) and phosphatidylserine on their surface [30].
As such, coated platelets ensure that the most potent
site of clot formation is localized to the desired target
[31,32]. This procoagulant profile is more likely to be
induced in younger platelet populations and strongly
supports prothombinase activity. The production of















Figure 2 Schematic TEG (upper half)/ ROTEM (lower half) trace
with the corresponding measured variables shown. Reaction
time (R)/clotting time (CT), Clot formation time (K, CFT), alpha angle (),
maximum amplitude (MA)/maximum clot firmness (MCF) and lysis
(Ly)/clot lysis (CL). Reproduced with permission from Stissing, et al. [46].
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loss of ΔΨm serves as a stimulant for the creation of
highly potent platelets, while the; inhibition of the mito-
chondrial permeability transition pore diminishes the
numbers of coated platelets [33]. Although the physio-
logic consequence of these platelets is currently unknown,
absence of these platelets leads to a bleeding diathesis in
canine models [34] whereas an up-regulation of coated
platelets may augment hemostasis. In clinical studies, di-
minished levels of coated platelets have been observed in
subarachnoid hemorrhage and increased levels correlate
with recurrent non-lacunar stroke and [35,36]. These di-
vergent observations suggest that coated platelets are an
important component of hemostasis. It is plausible that
coated platelets may potentially be a therapeutic target for
treatment of TIC.
Assessing platelet function in trauma patients
Intuitively, hemostasis is likely dependent on a sufficient
quantity of functional platelets. Observations across
many patient cohorts demonstrate a correlation between
the number of thrombocytes and the risk of death from
hemorrhage. Higher platelets count upon arrival to the
ICU has been associated with improved survival follow-
ing abdominal aortic aneurysm rupture [37]. Similarly, a
correlation between platelet count and survival has also
been demonstrated in patients with traumatic injury. In
a recent study of 389 severely injured patients, Brown
and colleagues noted that for every 50 × 109/L decrease
in platelet number, the odds of dying increased by 17%.
Importantly, this association held even when platelet
levels were within the normal laboratory range of 100–
450 × 109/L [10]. While current transfusion guidelines
recommend maintaining a platelet count of >50 × 109/L
this guideline may be insufficient in trauma patients and
an incremental survival advantage is seen with platelets
counts greater than 100 ×109/L [10].
Although it is clear that an adequate number of plate-
lets are important to survival, not all circulating platelets
may be functional. Translational research studies have
clearly demonstrated that critically injured patients deve-
lop physiologically significant platelet dysfunction, despite
normal platelet counts. Using impedance aggrenometry to
assess platelet function in 101 trauma patients, Kutcher
et al., noted that platelet clotting was abnormal in an as-
tounding 45% of patients on admission and in over 90%
during their ICU course [8]. When platelet function was
assessed using an agonist-impregnated cartridge that mea-
sures aperture occlusion by platelets, Jacoby et al. found
that platelets were activated but functionally impaired.
Notably, the most severely impaired platelet function was
observed in brain-injured patients and in those who ultim-
ately did not survive their injuries [38]. Interestingly, this
study mirrored the results of others, implicating traumaticbrain injury (TBI) as an independent risk factor for the de-
velopment of coagulopathy [39-43].
The mechanisms for coagulopathy associated with
TBI, however, have yet to be fully elucidated and may
represent a unique coagulopathy, independent from TIC.
One hypothesis is that the disruption of the protective
blood brain barrier in TBI exposes an endothelium rich in
tissue factor and platelet activating factor (PAF) [43,44].
Exposure to these two potent factors is hypothesized to
activate platelets to a point of exhaustion and subsequent
anergy [42,44]. The resultant platelet dysfunction limits
thrombin production and stabilization of clot formation,
thus compounding the effects of TIC in the polytrauma
patient [45].
The ability to test for platelet function in real time clin-
ical situations remains technically complex. Recently,
thromboelastography (TEG) and rotational thromboelas-
tography (ROTEM) have re-emerged as potentially useful
tools. TEG and ROTEM are viscoelastic assays that use a
rotational force to evaluate the mechanical resistance of a
clot over time. A computer analyzes the speed of clot initi-
ation, the kinetics of thrombus formation, clot strength
and lysis. The analysis is then graphically represented as a
visoleastic plot. The contributions from clotting factors, fi-
brinogen and platelets can be subsequently inferred based
on the morphology of the plot (Figure 2).
TEG and ROTEM
The use of TEG in evaluating platelet dysfunction is
an area of active investigation. Wolhauer et al., were one
of the first groups to report abnormal platelet function
in trauma patients using TEG-based mapping. Compared
to healthy controls, trauma patients had an 86% inhibition
of platelet response to ADP-agonism and a 44% inhibition
of arachadonic acid agonism of platelet aggregation. Fur-
thermore, in a subgroup of patients with traumatic brain
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from non-survivors [39], The results of this study support
the theory that platelet hypo-responsiveness may be a me-
diator of TIC.
Modified versions of TEG, for instance, the functional
fibrinogen TEG (FF-TEG) and platelet mapping TEG
(PM-TEG) have been developed to specifically differenti-
ate the contribution of fibrinogen from that of platelets
when evaluating a the coagulation profile. Using modi-
fied FF- TEG, investigators demonstrated that platelets,
not fibrinogen, determine the clot strength throughout
all time points of injury. Interestingly, FF-TEG levels pre-
dict outcomes; with every 1-mg/dL increase in FF-TEG
levels leading to a 1% decrease in mortality [47]. Although
not as well established, the PM-TEG eliminates the contri-
bution of thrombin and fibrin to examine platelet receptor
activity. The role of the PM-TEG in guiding blood product
therapy has yet to be clinically validated [48].
Platelet transfusions
Intuitively, low platelet counts and platelet dysfunction
should be easily corrected by a platelet transfusion. How-
ever, platelets stored for transfusion, may not perform as
well as native platelets. First described by Murphy et al. in
1971, the term “platelet storage lesion” (PSL) describes
how banked platelets undergo a time-dependent degra-
dation of function that mimics platelet activation and
subsequent exhaustion [49-51]. The storage lesion is cha-
racterized by in-vitro abnormalities including derange-
ments in metabolism [50,51] and reorganization of the
cell structure. Stored platelets undergo a structural change
and assume an activated phenotype by transforming from
a discoid to a dendritic shape. Additionally, the mean
platelet size decreases as platelets fragment into microve-
sicles. Glycoprotein expression is also altered with notable
dysfunction of the GpIb-X-V receptor. As previously de-
scribed, the ability of platelets to stabilize adhesion to the
endothelial glycoprotein matrix is due, in large part, to the
binding of glycoprotein1b of the GpIb-X-V receptor to
Von Willebrand’s Factor. During storage, platelet-secreted
metalloproteinases cleave the GpIbα and GpV portion of
this receptor thereby reducing its adhesive potential. Fur-
thermore, membrane clustering of the GpIb-X-V recep-
tors mark transfused platelets for premature clearance
from the bloodstream [52,53].
PSL also effects thrombus formation. Stored platelets
exhibit alterations in calcium handling that subsequently
impairs G -protein signaling as well as downstream phos-
phorylation of tyrosine kinases integral to TXA and ADP
activation. As such, stored platelets exhibit a diminished
response to ADP agonism and decreased aggregation. The
diminished receptivity towards ADP may also be sec-
ondary to activation of the GTPase Rap 1. Rap 1 acti-
vates the platelet surface receptor GPIIb/IIIa duringstorage. Treating stored platelet with kinases that medi-
ate Rap 1 activity restores resposiveness to ADP agon-
ism, and reduces PSL-associated platelet activation [52].
Minimizing the effects of the PSL on platelet respon-
siveness is essential to ensure that transfused platelets
remain functional.
A number of strategies have been investigated in or-
der to prevent the development platelet storage lesion.
In particular, platelet additive solutions have included a
number agents thought to may inhibit platelet activa-
tion, including theophylline, prostaglandin E1, throm-
bin inhibitors, L-carnitine , citrate, adenosine, quinacrine,
dipyramidole, ticlopidine, magnesium and potassium. Pro-
teomics is currently being utilized to provide a com-
parative analysis of protein alterations in stored platelets.
Developments from proteomics, such as the mechanism
of Rap 1, have helped to elucidate the peptide-based
changes associated with the PSL. There is hope that prote-
omics will continue to contribute to new investigational
therapies [54].
The activation of blood-banked platelets is an energetic-
ally expensive process that is also linked with decreased
mitochondrial potential [55]. Using high-resolution respi-
rometry and fluorescence activated cell signaling, Villaroel
et al. evaluated markers of mitochondrial function and
apoptosis during the course of platelet storage. Interest-
ingly, mitochondrial respiration and function deteriora-
ted significantly within 2 days of storage. Reactive oxygen
species and markers of apoptosis also significantly in-
creased throughout storage. When the functional activity
of platelets was tested by agonist stimulation, only 2% of
the platelets responded appropriately at 72 hrs. These
findings suggest that the integrity of mitochondrial respir-
ation is compromised well before the intended five-day
shelf life of stored platelets [56]. As such, additive solu-
tions that support mitochondrial function may mitigate
the platelet storage lesion and prolong the storage life of
platelets.
Conclusion
Platelets represent the next horizon in understanding
coagulopathy and the opportunities to expand upon the
current concepts are numerous. First and foremost, gai-
ning a deeper understanding of the cellular mechanisms
of platelet function will greatly enhance our model of
cell-based hemostasis and trauma induced coagulopathy.
Secondly, improvements in platelet function assays are
needed to help direct individualized resuscitation and to
identify patients at increased risk of dying from hemor-
rhage. Thirdly, mitochondrial bioenergetics appears to
have a central role in platelet activation, platelet sub-
specialization, and in the development of the platelet
storage lesion. As such, platelet mitochondrial function
deserves further study in the quest to improve in-vivo
Saillant and Sims Molecular and Cellular Therapies  (2014) 2:37 Page 6 of 7platelet function and blood banking. Moreover,, the close
association between platelet function and bioenergetics is
intriguing and may provide a real time, clinically available
surrogate marker of a patient’s mitochondrial profile [57].
The implications of studying platelets are far-reaching and
important in trauma, and it is clear that we have much to
accomplish.
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